Q BioMed, Jubilant Radiopharma Enter Commercial Pact

Once approved, Q BioMed to serve as contract manufacturer of non-opioid cancer palliation drug, Strontium-89 Chloride Injection, in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Q BioMed Inc. has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron, with Jubilant Radiopharma for the U.S. market.  Jubilant Radiopharma specializes in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.   Strontium-89 is an FDA-approved non-opioid radiopharmaceutical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters